

Press release

Ipsen will invest €55 million and plans to create 85 new jobs in Dreux (France) by 2011

Paris (France), 1 June 2007 - Ipsen (Euronext: FR0010259150; IPN) today announced its intention to strengthen its manufacturing facility and its pharmaceutical development center located in Dreux (France). By 2011, within its current investment program, Ipsen will have invested €55 million and plans to create 85 new jobs, including 15 highly qualified positions in R&D.

This ambitious scheme will allow Ipsen to bolster its research and development (R&D) in Dreux by focusing the site on three strategic activities: formulation, analytical development and manufacturing of batches intended for the preclinical and clinical research. Two new buildings will be built by 2009, while a third building will be renovated. Additionally, a large investment program will be implemented in Dreux, Ipsen's main manufacturing and supply unit, in order to support growing international sales.

Jean-Luc Bélingard, Ipsen's Chairman and CEO, stated, "By selecting Dreux as its international center of formulation and pharmaceutical development, Ipsen chose to reinforce its investments in France, a country that features exceptional intellectual, human, technological and scientific assets in the worldwide pharmaceutical area. Our Dreux facility, the Group's historical location, will be an important platform for our international development."

About the Dreux facility

Mainly focused on manufacturing and worldwide supply of drugs, Ipsen's facility at Dreux has 580 employees and includes today:

- A factory manufacturing 911 million sachets, 767 million tablets, 362 million capsules, 72.5 millions packs per year;
- A supply unit distributing more than 10,000 tons of drugs in 82 countries; and
- A formulation and pharmaceutical development unit.

About Ipsen

Ipsen is an innovation driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2006, R&D expenditure was €178.3 million, i.e. 20.7% of consolidated sales, which amounted to €861.7 million while total revenues amounted to €945.3 million (in IFRS). 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext™ (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the



“Système à Règlement Différé” (“SRD”) and the Group is part of the SBF 250 index. For more information on Ipsen, visit our website at www.ipсен.com.

Forward-looking statements

The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French Autorité des marchés financiers.

For further information:

Didier Véron, Director, Public Affairs and Corporate Communications

Tel.: +33 (0)1 44 30 42 38 - Fax: +33 (0)1 44 30 42 04

E-mail: didier.veron@ipсен.com

David Schilansky, Investor Relations Officer

Tel.: +33 (0)1 44 30 43 31 - Fax: +33 (0)1 44 30 43 21

E-mail: david.schilansky@ipсен.com